<DOC>
	<DOCNO>NCT00268177</DOCNO>
	<brief_summary>This study design look effect salmeterol/fluticasone propionate compare placebo airway inflammation patient chronic obstructive airway disease</brief_summary>
	<brief_title>Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Established clinical history chronic obstructive airway disease . Must current exsmokers smoke history least 10 packyears ( e.g . 20 cigarettes/day 10 year 10 cigarettes/day 20 year ) . Must reduce lung function , define Forced Expiratory Volume 1 second ( FEV1 ) 4080 % predict normal value . Diagnosis serious disease must chest Xray eliminate diagnosis COPD .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Airways</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Obstructive</keyword>
	<keyword>Chronic</keyword>
	<keyword>inflammation</keyword>
	<keyword>salmeterol/fluticasone propionate</keyword>
</DOC>